Market Intelligence on HER2-Negative Breast Cancer Industry 2025 – For Corporate Strategy and Innovation
This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the HER2-Negative Breast Cancer industry.
What is the expected value of the her2-negative breast cancer market over the forecast period?
The HER2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the rise in breast cancer cases, increased awareness about breast cancer, increased spending on healthcare, an aging population, and expanding healthcare infrastructures.
The HER2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing consumption of alcohol, increasing adoption of unhealthy lifestyles, increasing prevalence of obesity, increasing consumption of tobacco, and increasing need for effective treatment solutions. Major trends in the forecast period include innovations in diagnostic technologies, integration of targeted therapies, integration of immunotherapies, FDA approvals, and technological advancements.
Download Your Free Sample PDF:
What industry dynamics are acting as key growth drivers for the her2-negative breast cancer market?
Rising incidence of breast cancer cases is expected to propel the growth of the HER2-negative breast cancer market going forward. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, commonly originating in the ducts or lobules. The rising incidence of breast cancer cases can be attributed to several factors, including increased awareness and improved screening methods, leading to earlier and more frequent detection. HER2-Negative Breast Cancer plays a crucial role in advancing breast cancer research by providing insights into distinct tumor biology and treatment strategies, contributing to the development of more targeted therapies for patients. For instance, in June 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in the United States, 272,454 new cases of breast cancer were diagnosed among females in 2021, while 42,211 females succumbed to the disease in 2022. Therefore, the rising incidence of breast cancer cases is driving the growth of the HER2-negative breast cancer market.
What are the fastest-growing segments in the her2-negative breast cancer market forecast period?
The HER2-negative breast cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy
2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
View The Full Market Report:
What technological trends are expected to redefine the her2-negative breast cancer market?
Major companies operating in the HER2-negative breast cancer market are focusing on securing regulatory approvals to introduce new treatments, expand their product portfolios, and enhance their market presence. Regulatory approvals refer to the official authorization granted by government agencies, allowing companies to market and distribute drugs or treatments after meeting safety, efficacy, and quality standards. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, received FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval allows Itovebi to be used in combination with palbociclib and fulvestrant, significantly improving progression-free survival for patients compared to standard treatments. This new regimen provides a vital option for patients facing limited treatment choices, emphasizing the importance of biomarker testing to identify those who would benefit most from this therapy.
Which major players hold significant market share in the her2-negative breast cancer sector?
Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
Which regional segments are forecasted to witness the fastest growth in the her2-negative breast cancer market?
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The HER2-Negative Breast Cancer Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On HER2-Negative Breast Cancer Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment